Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus chemotherapy vs tislelizumab plus chemotherapy as first-line treatment for PD-L1–negative locally advanced or metastatic non-small cell lung cancer
CTR20223309Phase 3Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of QL1706 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Overall survival (OS). Started Feb 2023; status: active.
02
Drugs
QL1706
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20223309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223309.